XENE - Xenon Pharmaceuticals Inc.
NEXT EARNINGS:
Feb 26, 2026
(in 1 day)
EPS Est: $-1.20
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$56.60
DETAILS
HIGH:
$66.00
LOW:
$44.00
MEDIAN:
$58.00
CONSENSUS:
$56.60
UPSIDE:
26.37%
Market Cap:
3.46B
Volume:
931,579
Avg Volume:
872,558
52 Week Range:
26.74-46.6
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.93
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
CA
Employees:
316
IPO Date:
2014-11-05
EPS (TTM):
-3.01
P/E Ratio:
-13.03
Revenue (TTM):
N/A
Total Assets:
798.14M
Total Debt:
9.02M
Cash & Equiv:
142.71M
Rev Growth (5Y):
-100.0%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-31.3%
Debt/Equity:
0.01
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-03 | $-1.15 | $-1.16 | +0.9% | — | — | — |
| 2025-08-11 | $-1.07 | $-1.03 | -3.9% | — | — | — |
| 2025-05-12 | $-0.83 | $-0.94 | +11.7% | $7.5M | $1.9M | +293.4% |
| 2025-02-27 | $-0.84 | $-0.89 | +5.6% | — | $312500 | — |
| 2024-11-12 | $-0.81 | $-0.82 | +0.7% | — | $294120 | — |
| 2024-08-08 | $-0.75 | $-0.72 | -4.2% | — | — | — |
| 2024-05-09 | $-0.62 | $-0.69 | +10.1% | — | — | — |
| 2024-02-29 | $-0.64 | $-0.76 | +15.8% | $5.4M | $1.9M | +184.7% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 9.43M | 18.44M | 32.17M | 6.83M | 0 | 311,000 | 1.80M | 15.58M | 28.37M | 27.36M |
| Net Income | (234.33M) | (182.39M) | (125.37M) | (78.88M) | (28.84M) | (41.59M) | (34.50M) | (30.70M) | (23.00M) | (15.75M) | 13.02M | 12.03M |
| EPS | -3.01 | -2.73 | -2.06 | -1.77 | -0.83 | -1.54 | -1.78 | -1.71 | -1.48 | -1.10 | 0.94 | 0.42 |
| Total Assets | 798.14M | 964.80M | 754.15M | 572.01M | 189.19M | 147.70M | 122.43M | 46.12M | 67.49M | 63.95M | 87.42M | 54.49M |
| Total Debt | 9.02M | 10.90M | 10.44M | 8.26M | 3.31M | 16.45M | 15.01M | 6.80M | 0 | 0 | 0 | 0 |
| Cash & Equivalents | 142.71M | 148.64M | 57.24M | 175.69M | 45.01M | 24.75M | 67.75M | 20.49M | 17.09M | 58.65M | 72.03M | 37.95M |
| Operating Cash Flow | (181.39M) | (145.33M) | (98.43M) | (69.50M) | (48.12M) | (4.63M) | (34.72M) | (28.73M) | (19.57M) | (18.10M) | 266,000 | (3.32M) |
| Free Cash Flow | (184.46M) | (150.94M) | (101.32M) | (71.55M) | (50.76M) | (5.87M) | (35.23M) | (29.04M) | (19.85M) | (18.65M) | (1.26M) | (3.48M) |
| FCF per Share | -2.37 | -2.26 | -1.67 | -1.64 | -1.47 | -0.23 | -1.81 | -1.61 | -1.28 | -1.31 | -0.09 | -0.38 |
| Book Value | 754.90M | 927.92M | 721.50M | 550.03M | 171.35M | 91.98M | 103.30M | 35.93M | 63.90M | 61.03M | 72.78M | 24.12M |
| Cash & ST Investments | 626.90M | 638.08M | 592.09M | 551.77M | 177.00M | 141.36M | 119.31M | 43.67M | 64.15M | 58.65M | 84.04M | 49.28M |
| ROC Equity | -0.31 | -0.20 | -0.17 | -0.14 | -0.17 | -0.45 | -0.33 | -0.85 | -0.36 | -0.26 | 0.18 | 0.50 |